REGN posts strong early data for linvoseltamab combos in relapsed/refractory multiple myeloma, with ORRs up to 90% and high complete response rates.

Regeneron Pharmaceuticals (NasdaqGS:REGN) experienced a 2% increase in its share price over the past week as the company announced promising initial results from the Phase 1b LINKER-MM2 trial related ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory ...

GSK (GSK) stock in focus as its antibody drug conjugate Blenrep gains EMA recommendation for relapsed multiple myeloma with ...

GSK plc GSK announced that the FDA has approved its blockbuster respiratory drug, Nucala (mepolizumab), for a fifth ...

Predictive Oncology Inc. (NASDAQ: POAI) moves to leverage its vast biobank of more than 150,000 heterogenous live cell tumor ...

Rising prevalence, aging populations, and therapeutic innovation are reshaping the landscape of multiple myeloma care and driving sustained market gr ...

Astute Analytica is excited to announce the release of a comprehensive market assessment report titled “ Global Multiple Myeloma Treatment Market: Trends, Industry Competition Analysis, Revenue, and ...

Introduction: Multiple myeloma (MM) is a plasma cell malignancy comprising 10 ... of emerging therapies—next-generation proteasome inhibitors, immunomodulatory drugs, and CD38-targeting agents—aimed ...

Regeneron Pharmaceuticals gets a buy ... this firm has both a robust portfolio and a pipeline of future drug discovery across multiple clinical segments, along with impressive profit margins ...

May 12 (Reuters) - The U.S. Centers for Medicare and Medicaid Services (CMS) said on Monday that it would announce a list of 15 drugs eligible for a third round of Medicare price negotiations by ...